Asthma is a common chronic inflammatory condition of the airways that affects about 350 million people globally. In 5%-10% of individuals, it is severe, with considerable morbidity and high health care utilization. The goal of asthma management is disease control by reducing symptoms and exacerbations and reducing corticosteroid-related morbidity. The era of biologics has revolutionized the management of severe asthma. Biologics have changed our expectations for severe asthma, especially in those people with type-2 mediated immunity. We can now explore the potential for changing disease trajectory and inducing remission. However, biologics are not a panacea for all severe asthma sufferers and despite their success there remains substantial unmet clinical need. We review the pathogenesis of asthma, phenotyping the heterogeneity of asthma, currently licensed and future biologic agents, how to choose the initial biologic, assessing the response, remission and switching of biologic therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/resp.14520 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can Intravenous Caffeine Citrate Be Used for Severe Asthma Exacerbation in Children? A Retrospective Comparative Study.
J Paediatr Child Health
January 2025
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Aim: To assess the effectiveness of intravenous caffeine citrate in paediatric asthma exacerbation unresponsive to beta2-agonists and steroids.
Methods: A 10-year retrospective cohort study was conducted on asthmatic children unresponsive to beta2-agonists and steroids, who were treated with either intravenous caffeine citrate or magnesium sulphate. The study outcomes were changes in the Paediatric Respiratory Assessment Measure (PRAM) score, duration of oxygen therapy and paediatric intensive care unit (PICU) length-of-stay.
Relationship Between Bronchodilator Reversibility and Spirometry Response to Dupilumab in Type 2 High Uncontrolled Severe Asthma.
Clin Exp Allergy
January 2025
Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK.
Hypersensitivity Reactions to Anticonvulsants.
Curr Allergy Asthma Rep
January 2025
Rochester Regional Health, Rochester, NY, USA.
Background: Antiepileptics are the mainstay of treatment for seizure management. Immediate and delayed hypersensitivity reactions associated with antiepileptics are common. It is important to differentiate between these reactions as management and prognosis varies.
View Article and Find Full Text PDFFrom pediatric emergency department to pediatric intensive care unit: a retrospective study in a French Tertiary University hospital.
Arch Pediatr
January 2025
Pediatric emergency, Hôpital Nord, chemin des Bourrelly 13015 Marseille, France. Electronic address:
Objective: The management of a child presenting with a critical medical or surgical condition is a scarce event in the pediatric emergency department (PED). In this one year retrospective study, we have tried to better characterize the profile and care pathway of children who had been transferred to the neonatal or pediatric intensive care or critical care units (PICCU) after a visit to the PED, or died in PED.
Methods: Retrospective study of children who has been transferred to PICCU from the two PED of Marseille's University Hospital from the 1 of January 2022 until the 31 of December 2022.
Emerging biological treatments for asthma.
Expert Opin Emerg Drugs
January 2025
Department of Medical and Surgical Sciences, University "Magna Græcia" of Catanzaro - Catanzaro, Italy.
Introduction: Severe asthma is a chronic airway disease characterized by many pathomechanisms known as endotypes. Biological therapies targeting severe asthma endotypes have significantly improved the treatment of this disease, thus remarkably bettering patient quality of life.
Areas Covered: This review aims to describe current biological therapies for severe asthma, highlighting emerging ones.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!